Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...

The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with ...

BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual ...

On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation ...

The Chinese biopharmaceutical company achieved profitability milestone in its full-year financial performance driven by drug sales growth.

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results ...

Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, ...

Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion.Austin, United States, March 19, 2026 (GLOBE NEWSWIRE) -- ...

Autolus Therapeutics (NASDAQ:AUTL) executives highlighted a “very good first year of launch” for AUCATZYL during the ...

Supreme Court bars stem cell therapy for Autism Spectrum Disorder as NMC limits HSCT use to 32 approved blood cancers and ...